Facebook Twitter LinkedIn

Our mission is to provide researchers around the world with products and services to enhance and streamline their R&D effort thereby enabling scientific advancement and facilitating entry of newly developed drugs and diagnostics into rapidly growing markets. We are also increasingly focussed on embedding our products and technologies in diagnostic end-products and solutions.
Our product and services offering is underpinned by unique, innovative and proprietary technologies which are developed to both accelerate and simplify research and product development work flows, addressing the following core markets:

  • Genomics research: Next Generation Sequencing (NGS)

    Gene variations predispose many complex genetic diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s disease as well affecting a patient’s response to certain drug treatments including adverse side effects. Being able to read the variations in our genetic code is the key to understanding and ultimately treating many gene related conditions that impact our wellbeing and life expectancy. Whole genome sequencing by NGS enables scientists to read and determine the complete DNA sequence of an organism.

    Driven by an increase in technological advancements in NGS platforms, a decline in the cost of sequencing, and an increase in the use of NGS within research, the global Next Generation Sequencing market is projected to reach USD 12.45 billion by 2022, growing at a CAGR of 20.5% in the forecast period 2017-2022 (marketsandmarkets.com, June 2018).

    The technology boasts sensitivity, accuracy, coverage and quality, enabling accurate and high-quality amplification of the smallest amounts of DNA to a quantifiable level. TruePrime is therefore well positioned to take a pivotal role in applications such as single cell analysis, liquid biopsy (both very important fields of research for oncology applications) or forensics where the amount of DNA is critically low and requires accurate and reliable amplification.

    Successful sequencing relies on the availability of sufficient quantities of high quality DNA which can be hard to obtain due to the amplification processes. The amplification of DNA. i.e. the process of copying DNA molecules through whole genome amplification, is an extremely sensitive process subject to bias, inaccuracy and contamination. To address these issues, we have developed TruePrimeTM technology, a truly ground-breaking technology that accurately amplifies DNA in biological samples, enabling the processing of sufficient, high quality DNA required for Next Generation Sequencing.

  • Clinical diagnostics: Liquid Biopsy, Oncology

    With a market projected to reach USD 2.04 Billion by 2022 and growing at a CAGR of 8.4%, liquid biopsy, the analysis of tumor-derived DNA fragments in the blood, has the potential to revolutionize diagnostic medicine, particularly in oncology.

    In contrast to conventional biopsies which require surgical intervention, liquid biopsy can be performed on a regular basis thereby allowing frequent monitoring of a patient’s response to treatment. Moreover in light of the dynamic nature of tumors comprising varying populations of cells with different mutation profiles, liquid biopsy can provide information about the entire tumor mutation profile rather than the fractional view which is obtained through the conventional biopsy approach.

    Expedeon has developed two different types of technologies to amplify cell free DNA present in bodily fluids. Our TruePrime Necrotic cell-free/ Liquid Biopsy (LB) technology offers a method for accurate and selective amplification of long fragment DNA. The presence of long fragment cell free DNA in bodily fluids is often related to necrotic events (uncontrolled cell death) which can occur when tumor growth is putting strain and stress on the cells. As a result, long fragment DNA is often cancerous in nature and is therefore of special interest for further investigation. TruePrime LB selectively and accurately amplifies the long fragment DNA to a level suitable for further analysis.

    The most recent addition to our range of TruePrime technologies for liquid biopsy is our TruePrime apoptotic cell-free DNA amplification technology, launched in December 2017. This novel and unique technology focuses on the amplification of small fragments of DNA which are generated when cells undergo the natural termination process at the end of their life (apoptosis). These small apoptotic fragments are notoriously difficult to amplify and TruePrime apoptotic is the only product currently available to reliably and accurately amplify these small DNA fragments.
    Both methods enable generation of sufficient DNA material permitting reliable NGS analysis for every liquid biopsy sample. In addition to becoming a valuable tool in oncology research, TruePrime is expected to have utility in the field of precise medicine and has the potential to take up a pivotal role in the diagnosis and monitoring of cancer. Expedeon’s TruePrime technology is well positioned to take a central role in the highly valuable Liquid Biopsy market.

  • Point-of-care/rapid diagnostics

    The benefit of point-of-care diagnostic tests in the provision of immediate results within patient care, combined with a high prevalence of chronic disease worldwide, a growing paediatric population and the decentralisation of laboratory testing, has seen a rapid growth in the POC diagnostic market, which is projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017, growing at a CAGR of 10.0% (marketsandmakets.com, June 2018). Expedeon’s products and technologies have significant utility and applicability in clinical and point of care diagnostics. One of our key objectives is to supply diagnostics companies with our products and embed our technologies in their diagnostic end products.

    Expedeon’s novel gold nanoparticle manufacturing process is key to our offering within this market. We have developed a unique method that enables the bulk production of ultra-high quality colloidal gold, a dominant reporter method for point-of-care lateral flow assays. The installation of bulk manufacturing capabilities allows us to support large diagnostic customers on a global scale.
    Further to this, Expedeon are well established as a key driver of innovative technologies within the lateral flow assay market providing customers with products that enable streamlined R&D of their diagnostic tests, enabling rapid development of POC diagnostic tools for entry into this rapidly growing market.

    In addition to our product offering being suitable for incorporation in diagnostic products, the Company also offers services to assist its customers with their product development. These services include antibody conjugation optimisation, lateral flow assay (LFA) and enzyme linked immune sorbent assay (ELISA) development services. Moreover, the Company has partnered with Abingdon Health a leading manufacturer of diagnostic tests to ensure a smooth transition of proof of concept designs into manufacturing.

    The supply of products and technologies into the high volume diagnostic market segment is expected to continue growing in 2018 and beyond and it is the Company’s objective to seek to embed TruePrime technology into Liquid Biopsy diagnostic tests which would unlock the commercial potential of this exceptional technology.

  • Proteomics: personalised medicine

    Proteomics is the study of the structure and function of proteins and is used in a variety of applications including drug discovery, diagnosis and the development of personalised medicines and as well as the identification of bio-markers for disease diagnosis.

    An increased awareness of the benefits of personalised medicines has resulted in increased funding and stronger R&D expenditure within this field, meaning the market is predicted to reach USD 21.87 Billion by 2021, growing at a CAGR of 11.7% from 2016.

    Expedeon’s product range serving this market is ever expanding covering applications such as gel electrophoresis and western blotting, both techniques widely used across life sciences laboratories worldwide. Through the acquisition of CBS scientific in 2016, the company has bolstered its position and expertise in this lucrative field. At its facilities in Cambridge, UK and San Diego, USA Expedeon manufactures a comprehensive range of innovative, patented high quality products and devices for use in proteomics research which offer our customers ease to use products with enhanced performance and excellent reproducibility compared to alternative approaches.